References

gnck

Колопроктология

Koloproktologia

2073-75562686-7303

Russian Association of Coloproctology

10.33878/2073-7556-2023-22-1-10-44

gnck-1805

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Язвенный колит (К51), взрослые

Ulcerative colitis (K51), adults

Шелыгин

Ю. А.

Shelygin

Yu. A.

ул. Саляма Адиля, д. 2, г. Москва, 123423,

ул. Баррикадная, д. 2/1, г. Москва, 123995

Yuri A. Shelygin

Salyama Adilya st., 2, Moscow, 123423;

Barrikadnaya st., 2/1, Moscow, 123995

Ивашкин

В. Т.

Ivashkin

V. T.

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Vladimir T. Ivashkin

Trubetskaya st., 8, bld. 2, Moscow, 119991

Белоусова

Е. А.

Belousova

E. A.

пр-т Мира, д. 61/2, г. Москва, 129090

Elena A. Belousova

Prospect Mira, 61/2, Moscow, 129090

Решетов

И. В.

Reshetov

I. V.

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Igor V. Reshetov

Trubetskaya st., 8, bld. 2, Moscow, 119991

Маев

И. В.

Maev

I. V.

ул. Делегатская, д. 20, стр. 1, г. Москва, 127473

Igor V. Maev

Delegatskaya st., 20, bld. 1, Moscow, 127473

Ачкасов

С. И.

Achkasov

S. I.

ул. Саляма Адиля, д. 2, г. Москва, 123423,

ул. Баррикадная, д. 2/1, г. Москва, 123995

Salyama Adilya st., 2, Moscow, 123423;

Barrikadnaya st., 2/1, Moscow, 123995

Абдулганиева

Д. И.

Abdulganieva

D. I.

ул. Бутлерова, д. 49, г. Казань, 420012

Diana I. Abdulganieva

Butlerova st., 49, Kazan, 420012

Алексеева

О. А.

Alekseeva

O. A.

пл. Минина и Пожарского, д. 10/1, г. Нижний Новгород, 603005

Olga A. Alekseeva

Minin and Pozharsky sq., 10/1, Nizhny Novgorod, 603005

Бакулин

И. Г.

Bakulin

I. G.

ул. Кирочная, д. 41, г. Санкт-Петербург, 191015

Igor G. Bakulin

Kirochnaya st., 41, St. Petersburg, 191015

Барышева

О. Ю.

Barysheva

O. Yu.

пр-т Ленина, д. 33, г. Петрозаводск, 185910

Olga Yu. Barysheva

Lenin Ave., 33, 185910, Petrozavodsk

Болихов

К. В.

Bolikhov

K. V.

ул. Лобачевского, д. 42, корп. 4, г. Москва, 119415

Kirill V. Bolikhov

Lobachevsky str., 42, bld. 4, Moscow, 119415

Варданян

А. В.

Vardanyan

A. V.

ул. Саляма Адиля, д. 2, г. Москва, 123423

Armen V. Vardanyan

Salyama Adilya st., 2, Moscow, 123423

Веселов

А. В.

Veselov

A. V.

ул. Муравьева-Амурского, д. 32, г. Хабаровск, 680000

Alexey V. Veselov

Muravyov-Amursky st., 32, Khabarovsk, 680000

Веселов

В. В.

Veselov

V. V.

ул. Саляма Адиля, д. 2, г. Москва, 123423,

ул. Баррикадная, д. 2/1, г. Москва, 123995

Viktor V. Veselov

Salyama Adilya st., 2, Moscow, 123423,

Barrikadnaya st., 2/1, Moscow, 123995

Головенко

О. В.

Golovenko

O. V.

ул. Саляма Адиля, д. 2, г. Москва, 123423,

ул. Баррикадная, д. 2/1, г. Москва, 123995

Oleg V. Golovenko

Salyama Adilya st., 2, Moscow, 123423,

Barrikadnaya st., 2/1, Moscow, 123995

Губонина

И. В.

Gubonina

I. V.

Литейный пр-т., д. 55А, г. Санкт-Петербург, 191014

Irina V. Gubonina

Liteiny pr., 55A, St. Petersburg, 191014

Денисенко

В. Л.

Denisenko

V. L.

пр-т Фрунзе, д. 27, г. Витебск, 210023

Valery L. Denisenko

Frunze Ave., 27, Vitebsk, 210023

Долгушина

А. И.

Dolgushina

A. I.

ул. Воровского, д. 64, г. Челябинск, 454092

Anastasia I. Dolgushina

Vorovskogo st., 64, Chelyabinsk, 454092

Кашников

В. Н.

Kashnikov

V. N.

Vladimir N. Kashnikov

Salyama Adilya st., 2, Moscow, 123423

Князев

О. В.

Knyazev

O. V.

ш. Энтузиастов, д. 86, г. Москва, 111123

Oleg V. Knyazev

shosse Entuziastov, 86, Moscow, 111123

Костенко

Н. В.

Kostenko

N. V.

ул. Бакинская, д. 121, г. Астрахань, 414000

Nikolay V. Kostenko

Bakinskaya st., 121, Astrakhan, 414000

Лахин

А. В.

Lakhin

A. V.

ул. Московская, д. 6А, г. Липецк, 398055

Aleksandr V. Lakhin

Moskovskaya st., 6A, Lipetsk, 398055

Макарчук

П. А.

Makarchuk

P. A.

пр-т Мира, д. 61/2, г. Москва, 129090

Pavel A. Makarchuk

Prospect Mira, 61/2, Moscow, 129090

Москалев

А. И.

Moskalev

A. I.

Aleksey I. Moskalev

Salyama Adilya st., 2, Moscow, 123423

Нанаева

Б. А.

Nanaeva

B. A.

ул. Саляма Адиля, д. 2, г. Москва, 123423

Bella A. Nanaeva

Salyama Adilya st., 2, Moscow, 123423

Никитин

И. Г.

Nikitin

I. G.

ул. Островитянова, д. 1, г. Москва, 117997

Igor G. Nikitin

Ostrovityanova st., 1, Moscow, 117997

Никитина

Н. В.

Nikitina

N. V.

пр-т Мира, д. 61/2, г. Москва, 129090

Natalia V. Nikitina

Prospect Mira, 61/2, Moscow, 129090

Одинцова

А. Х.

Odintsova

A. Kh.

Оренбургский тракт, д. 138, г. Казань, 420064

Alfiya Kh. Odintsova

Orenburgsky Trakt, 138, Kazan, 420064

Омельяновский

В. В.

Omelyanovskiy

V. V.

Vitaly V. Omelyanovskiy

Barrikadnaya st., 2/1, Moscow, 123995

Ощепков

А. В.

Оshchepkov

A. V.

ул. Волгоградская, д. 185, г. Екатеринбург, 620102

Аndrey V. Оshchepkov

Volgogradskaya st., 185, Yekaterinburg, 620102

Павленко

В. В.

Pavlenko

V. V.

ул. Мира, д. 310, г. Ставрополь, 355017

Vladimir V. Pavlenko

Mira st., 310, Stavropol, 355017

Полуэктова

Е. А.

Poluektova

E. A.

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991,

Elena A. Poluektova

Trubetskaya st., 8, bld. 2, Moscow, 119991

Ситкин

С. И.

Sitkin

S. I.

ул. Кирочная, д. 41, г. Санкт-Петербург, 191015

Stanislav I. Sitkin

Kirochnaya st., 41, St. Petersburg, 191015

Сушков

О. И.

Sushkov

O. I.

ул. Саляма Адиля, д. 2, г. Москва, 123423

Oleg I. Sushkov

Salyama Adilya st., 2, Moscow, 123423

Тарасова

Л. В.

Tarasova

L. V.

Московский пр-т, д. 15, г. Чебоксары, 428015

Larisa V. Tarasova

Moskovsky Ave., 15, Cheboksary, 428015

Ткачев

А. В.

Tkachev

A. V.

пер. Нахичиванский, д. 29, г. Ростов-на-Дону, 344022

Aleksandr V. Tkachev

Nakhchivansky lane, 29, Rostov-on-Don, 344022

Тимербулатов

В. М.

Тimerbulatov

V. M.

ул. Заки Валиди, д. 47, г. Уфа, 450008

Vil M. Тimerbulatov

Zaki Validi st., 47, Ufa, 450008

Успенская

Ю. Б.

Uspenskaya

Yu. B.

пер. Столярный, д. 3, корп. 2, г. Москва, 123242

Yulia B. Uspenskaya

per. Stolyarny, 3, bld. 2, Moscow, 123242

Фролов

С. А.

Frolov

S. A.

ул. Саляма Адиля, д. 2, г. Москва, 123423

Sergey A. Frolov

Salyama Adilya st., 2, Moscow, 123423

Хлынова

О. В.

Khlynova

O. V.

ул. Петропавловская, д. 26, г. Пермь, 614000

Olga V. Khlynova

Petropavlovskaya st., 26, Perm, 614000

Чашкова

Е. Ю.

Chashkova

E. Yu.

ул. Борцов Революции, д. 1, г. Иркутск, 664003

Elena Yu. Chashkova

Bortsov Revolution st., 1, Irkutsk, 664003

Чеснокова

О. В.

Chesnokova

O. V.

ул. Алеутская, д. 57, г. Владивосток, 690091

Olga V. Chesnokova

Aleutskaya st., 57, Vladivostok, 690091

Шапина

М. В.

Shapina

M. V.

ул. Саляма Адиля, д. 2, г. Москва, 123423,

ул. Баррикадная, д. 2/1, г. Москва, 123995

Marina V. Shapina

Salyama Adilya st., 2, Moscow, 123423,

Barrikadnaya st., 2/1, Moscow, 123995

Шептулин

А. А.

Sheptulin

A. A.

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Arcadiy A. Sheptulin

Trubetskaya st., 8, bld. 2, Moscow, 119991

Шифрин

О. С.

Shifrin

O. S.

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Oleg S. Shifrin

Trubetskaya st., 8, bld. 2, Moscow, 119991

Шкурко

Т. В.

Shkurko

T. V.

ул. Саляма Адиля, д. 2, г. Москва, 123423

Tatiana V. Shkurko

Salyama Adilya st., 2, Moscow, 123423

Щукина

О. Б.

Shchukina

O. B.

ул. Льва Толстого, д. 6-8, г. Санкт-Петербург, 197022

Oksana B. Shchukina

Lva Tolstoy st., 6-8, St. Petersburg, 197022

ФГБУ «НМИЦ колопроктологии имени А.Н. Рыжих» Минздрава России; ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияRyzhikh National Medical Research Center of Coloproctology; Russian Medical Academy of Continous Professional EducationRussian Federation

ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation

ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»РоссияMoscow Regional Research and Clinical InstituteRussian Federation

ФГБОУ ВО МГМСУ им. А.И. Евдокимова Минздрава РоссииРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation

ФГБОУ ВО Казанский ГМУ Минздрава РоссииРоссияKazan State Medical UniversityRussian Federation

ФГБОУВО Приволжский исследовательский медицинский университет Минздрава РоссииРоссияPrivolzhsky Research Medical UniversityRussian Federation

ФГБОУ ВО Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава РоссииРоссияNorth-Western State Medical University named after I.I. MechnikovRussian Federation

ФГБОУ ВО ПетрГУ Минобрнауки РоссииРоссияPetrozavodsk State UniversityRussian Federation

Клиника «К+31» на ЛобачевскогоРоссияClinic «K+31» on LobachevskyRussian Federation

ФГБУ «НМИЦ колопроктологии имени А.Н. Рыжих» Минздрава РоссииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian Federation

Министерство здравоохранения Хабаровского краяРоссияMinistry of Health of the Khabarovsk TerritoryRussian Federation

Многопрофильная клиника СкандинавияРоссияMultidisciplinary clinic ScandinaviaRussian Federation

УО «Витебский государственный медицинский университет»БеларусьEducational Establishment Vitebsk State Order of Peoples’ Friendship Medical UniversityBelarus

ФГБОУ ВО Южно-Уральский государственный медицинский университет Минздрава РоссииРоссияFederal State Budgetary Educational Institution of Higher Education «South-Ural State Medical University» of the Ministry of Healthcare of the Russian FederationRussian Federation

ГБУЗ «МКНЦ имени А.С. Логинова» Департамента здравоохранения МосквыРоссияGBUZ Moscow Clinical Scientific Center named after Loginov MHDRussian Federation

ФГБОУ ВО Астраханский ГМУ Минздрава РоссииРоссияFederal State Budgetary Educational Institution of Higher Education «Astrakhan State Medical University» of the Ministry of Health of the Russian FederationRussian Federation

ГУЗ «Липецкая областная клиническая больница»РоссияGUZ «Lipetsk Regional Clinical Hospital»Russian Federation

ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian Federation

ГАУЗ «РКБ» Минздрава Республики ТатарстанРоссияGAUZ «RCH» of the Ministry of Health of the Republic of TatarstanRussian Federation

ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияRussian Medical Academy of Continous Professional EducationRussian Federation

ГБУЗ СО «СОКБ №1» Минздрава Свердловской областиРоссияGBUZ SO «SOKB No. 1» of the Ministry of Health of the Sverdlovsk RegionRussian Federation

ФГБОУ ВО Ставропольский государственный медицинский университет Минздрава РоссииРоссияStavropol State Medical UniversityRussian Federation

ФГБОУ ВО Чувашский государственный университет им. И.Н. Ульянова Минздрава РоссииРоссияFederal State Budgetary Educational Institution of Higher Education «Chuvash State University named after I.N. Ulyanov»Russian Federation

ФГБОУ ВО Ростовский государственный медицинский университет Минздрава РоссииРоссияFederal State Budgetary Educational Institution of Higher Education «Rostov State Medical University» of the Ministry of Health of the Russian FederationRussian Federation

ФГБОУ ВО «БГМУ» Минздрава РоссииРоссияBashkir State Medical UniversityRussian Federation

ООО «Медсанчасть №14»РоссияLLC «Medsanchast No. 14»Russian Federation

ФГБОУ ВО ПГМУ им. академика Е.А. Вагнера Минздрава РоссииРоссияPerm State Medical University named after E.A. Wagner (PSMU) of the Ministry of Healthcare of the Russian FeaderationRussian Federation

ФГБНУ «Иркутский научный центр хирургии и травматологии»РоссияFederal State Budgetary Scientific Institution «Irkutsk Scientific Center for Surgery and Traumatology»Russian Federation

ГБУЗ «Приморская краевая клиническая больница № 1»РоссияGBUZ «Primorsky Regional Clinical Hospital No. 1»Russian Federation

ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава РоссииРоссияFirst St. Petersburg State Medical University named after Academician I.P. Pavlov of the Ministry of Health of RussiaRussian Federation

2023

03032023

2211044

Copyright © Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А., Решетов И.В., Маев И.В., Ачкасов С.И., Абдулганиева Д.И., Алексеева О.А., Бакулин И.Г., Барышева О.Ю., Болихов К.В., Варданян А.В., Веселов А.В., Веселов В.В., Головенко О.В., Губонина И.В., Денисенко В.Л., Долгушина А.И., Кашников В.Н., Князев О.В., Костенко Н.В., Лахин А.В., Макарчук П.А., Москалев А.И., Нанаева Б.А., Никитин И.Г., Никитина Н.В., Одинцова А.Х., Омельяновский В.В., Ощепков А.В., Павленко В.В., Полуэктова Е.А., Ситкин С.И., Сушков О.И., Тарасова Л.В., Ткачев А.В., Тимербулатов В.М., Успенская Ю.Б., Фролов С.А., Хлынова О.В., Чашкова Е.Ю., Чеснокова О.В., Шапина М.В., Шептулин А.А., Шифрин О.С., Шкурко Т.В., Щукина О.Б., 2023

2023

Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А., Решетов И.В., Маев И.В., Ачкасов С.И., Абдулганиева Д.И., Алексеева О.А., Бакулин И.Г., Барышева О.Ю., Болихов К.В., Варданян А.В., Веселов А.В., Веселов В.В., Головенко О.В., Губонина И.В., Денисенко В.Л., Долгушина А.И., Кашников В.Н., Князев О.В., Костенко Н.В., Лахин А.В., Макарчук П.А., Москалев А.И., Нанаева Б.А., Никитин И.Г., Никитина Н.В., Одинцова А.Х., Омельяновский В.В., Ощепков А.В., Павленко В.В., Полуэктова Е.А., Ситкин С.И., Сушков О.И., Тарасова Л.В., Ткачев А.В., Тимербулатов В.М., Успенская Ю.Б., Фролов С.А., Хлынова О.В., Чашкова Е.Ю., Чеснокова О.В., Шапина М.В., Шептулин А.А., Шифрин О.С., Шкурко Т.В., Щукина О.Б.

Shelygin Y.A., Ivashkin V.T., Belousova E.A., Reshetov I.V., Maev I.V., Achkasov S.I., Abdulganieva D.I., Alekseeva O.A., Bakulin I.G., Barysheva O.Y., Bolikhov K.V., Vardanyan A.V., Veselov A.V., Veselov V.V., Golovenko O.V., Gubonina I.V., Denisenko V.L., Dolgushina A.I., Kashnikov V.N., Knyazev O.V., Kostenko N.V., Lakhin A.V., Makarchuk P.A., Moskalev A.I., Nanaeva B.A., Nikitin I.G., Nikitina N.V., Odintsova A.K., Omelyanovskiy V.V., Оshchepkov A.V., Pavlenko V.V., Poluektova E.A., Sitkin S.I., Sushkov O.I., Tarasova L.V., Tkachev A.V., Тimerbulatov V.M., Uspenskaya Y.B., Frolov S.A., Khlynova O.V., Chashkova E.Y., Chesnokova O.V., Shapina M.V., Sheptulin A.A., Shifrin O.S., Shkurko T.V., Shchukina O.B.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.ruproctology.com/jour/article/view/1805

References1

Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterology. 2010;30:17–20.

D’Haens G, Sandborn WJ, Feagan BJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.

Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.

Dignass A, Eliakim R, Magro F, Maaser Ch, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012 Dec;6(10):965–90. doi: 10.1016/j.crohns.2012.09.003

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.

De Groof EJ, Rossen NGM, Van Rhijn BD, et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a population based cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016;28:1065–72.

Qiu Y, Wen Ren W, Liu Y, Chen W, Pan X, et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine. 2020;27:100544. doi: 10.1016/j.eclinm.2020.100544

Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П., Алексеенко С.А. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–463. doi: 10.18786/2072-0505-2018-46-5-445-463

Belousova E.A., Abdulganieva D.I., Alekseeva O.P., Alekseenko S.A. et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Almanac of clinical medicine. 2018;46(5):445–463. (in Russ.). doi: 10.18786/2072-0505-2018-46-5-445-463

Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–97.

Katsanos KH, Vermeire S, Christodoulou DK, Riis L, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007;75:113–21.

Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5–36.

Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb;43(4):482–513.

Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):654–664.

Ачкасов С.И., Шапина М.В., Веселов В.В., Варданян А.В., Мингазов А.Ф., и соавт. Предикторы колэктомии у пациентов со сверхтяжелым язвенным колитом. Колопроктология. 2020;19(3):37–48. doi: 10.33878/2073-7556-2020-19-3-37-48

Achkasov S.I., Shapina M.V., Veselov V.V., Vardanyan A.V., Mingazov A.F., et al. Predictors of colectomy in patients with «extremely severe» ulcerative colitis. Koloproktologia. 2020;19(3):37–48. (in Russ.). doi: 10.33878/2073-7556-2020-19-3-37-48

Chen JH, Andrews JM, Kariyawasam V, Moran N. IBD Sydney Organization and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis — evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul;44(2):127–44.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.

Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011;15:44–49.

Grigorieva G.A., Meshalkina N.Yu. On the problem of systemic manifestations of inflammatory bowel diseases. Pharmateca. 2011;15:44–49. (in Russ.).

Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518–32.

Perler B, Ungaro R, Baird G, Malette M, et al. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a communitybased inceptive cohort. BMC Gastroenterol. 2019;19:47.

Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464– 86.

Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035–43.

Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–71.

Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:2–10.

Carter MJ, Lobo AJ, Travis SP; IBD Section. British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:1–16.

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, et al. European Crohn’s and Colitis Organization [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Jan 28;11(7):769–84. doi: 10.1093/ecco-jcc/jjx009

Travis SP, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J, Sutherland LR, editors. Inflammatory Bowel Diseases. London: Churchill Livingstone. 2003:169–81.

Lucendo AJ, Arias Á, Roncero Ó, Hervías D, et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Sao Paulo Med J. 2014;132(3):140–6.

Irwin JR, Ferguson E, Simms LA, Hanigan K, et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease. Dig Dis Sci. 2019 Feb;64(2):503– 517.

Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015 Aug;21(8):1769–75.

Feng JR, Qiu X, Wang F, Chen PF, et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn’s Disease. Gastroenterol Res Pract. 2017. doi: 10.1155/2017/3526460

Yoon JY, Park SJ, Hong SP, Kim TI, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr;59(4):829–37.

Yamamoto-Furusho JK, Sánchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010 OctDec;9(4):397–401.

Archampong EQ, Harris J, Clark CG. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov;13(11):880–6.

Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug;9(3):140–3.

Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Göttl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):418–422.

Axelrad JE, Joelson A, Green PHR, Lawlor G, et al. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530–1539. doi: 10.1038/s41395-018-0211-8

Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:345–351.

Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–344.

Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1432–42.

Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–50.

Kim JJ, Simpson N, Klipfel N, Debose R, et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr;55(4):1059–65. doi: 10.1007/s10620-010-1126-4

Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, et al. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion. 2017;96(3):142–148. doi: 10.1159/000479865

Lin WC, Chang CW, ChenMJ, Hsu TC, et al. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748

Bansal J, Jenaw RK, Rao J, et al. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012 Apr;19(2):115–9. doi: 10.1007/s10140-011-1007-y

Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2013;7(12):982–1018.

Tanaka M, Saito H, Fukuda S, Sasaki Y, et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol. 2000 Mar;35(3):281–6.

Parente F, Greco S, Molteni M, et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003;18:1009–1016.

Socaciu M, Ciobanu L, Diaconu B, Hagiu C, et al. Non-Invasive Assessment of Inflammation and Treatment Response in Patients with Crohn’s Disease and Ulcerative Colitis using Contrast-Enhanced Ultrasonography Quantification. J Gastrointestin Liver Dis. 2015 Dec;24(4):457–65. doi: 10.15403/jgld.2014.1121.244.chr

Smith R, Taylor K, Friedman AB, et al. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis. 2020 May 21;14(4):465–479. doi: 10.1093/ecco-jcc/jjz163

Kılıçkesmez O, Soylu A, Yaşar N, Demirbaş T, et al. Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis? Diagn Interv Radiol. 2010 Dec;16(4):293–8. doi: 10.4261/1305-3825.DIR.2989-09.1

Jia Y, Li C, Yang X, Dong Z, et al. CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis. BMC Gastroenterol. 2018 Nov 9;18(1):173. doi: 10.1186/s12876-018-0890-z

Gashin L, Villafuerte-Galvez J, Leffler DA, et al. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr;21(4):793–800. doi: 10.1097/MIB.0000000000000321

Милько В.И., Минцер О.П., Топчий Т.В., Корсуновский А.А. Клиническая оценка данных ирригоскопии при неспецифическом язвенном колите. Вестник рентгенологии и радиологии. 1983;5:46–50.

Milko V.I., Mintser O.P., Topchiy T.V., Korsunovsky A.A. Clinical evaluation of irrigoscopy data in nonspecific ulcerative colitis. Bulletin of Radiology and Radiology. 1983;5:46–50. (in Russ.).

Fraser GM, Findlay JM. The double contrast enema in ulcerative and Crohn’s colitis. Clin Radiol. 1976 Jan;27(1):103–12

Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., и соавт. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(6):56–60.

Ivashkin V.T., Sheptulin A.A., Shifrin O.S., Galimova S.F., et al. Microscopic colitis: clinical forms, diagnosis, treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(6):56–60 (in Russ.).

Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: 10.1038/ajg.2015.233

Тurner D, Ricciuto A, Lewis A, et al. International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570–1583. Epub 2021 Feb 19. PMID: 33359090. doi: 10.1053/j.gastro.2020.12.031

Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(3):58–62.

Khalif I.L. Therapeutic tactics for ulcerative colitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(3):58–62. (in Russ.).

Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013;2:42–46.

Belousova E.A., Nikitina N.V., Tsodikova O.M. Treatment of ulcerative colitis of mild and moderate course. Pharmateca. 2013;2:42–46 (in Russ.).

Reinisch W, Reinink AR, Higgins PDR. Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2015;13:635–642.

Dias CC, Rodrigues PP, da Costa-Pereira A, et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156–63.

Annese V, Beaugerie L, Egan L, Biancone L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9(11):945–65.

Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и соавт. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. Альманах клинической медицины. 2020;48(6):422–436. doi: 10.18786/2072-0505-2020-48-050

Abdulganieva D.I., Bakulev A.L., Belousova E.A. et al. Early administration of genetically engineered biological drugs in immunoinflammatory diseases: opportunities and prospects. The position of experts. Almanac of Clinical Medicine. 2020;48(6):422–436 (in Russ.). doi: 10.18786/2072-0505-2020-48-050

Dinesen LC, Walsh AJ, Protic MN, Heap G, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431–437, doi: 10.1016/j.crohns.2010.02.001

Marshall JK, Thabane M, Steinhart AH, Newman JR, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 2010, Issue 1. Art. No.:CD004115. doi: 10.1002/14651858.CD004115

Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56:513–2256,57.

Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775– 81.

Pokrotnieks J, Sitkin S. A proposed treatment algorithm for mild to moderate ulcerative colitis–with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018 Jun;53(6):799–800. doi: 10.1007/s00535-018-1458-y

Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.

Safdi M, DeMicco M, Sninsky C, Banks P, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.

Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 18;(5):CD000478. doi: 10.1002/14651858.CD000478.pub4

Ahmed I, Kassem W, Salam Y, Furnari M, Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J Dig Dis. 2018 Oct;10(4):220–229. doi: 10.15171/mejdd.2018.114

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000543.

Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and metaanalysis. Am J Gastroenterol. 2011;106:601–16.

Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. The American journal of gastroenterology. 2012;107:167–76.

Nikfar S, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of imp rovement and maintenance of remission in patients with ulcerative colitis. Digestive diseases and sciences. 2009;54(6):1157–1170.

Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3:210–8.

Zhang Y, Chen D, Wang F, Li X, Xue X, et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019 Mar;52(2):e12559. Epub 2019 Jan 18. doi: 10.1111/cpr.12559

Danielsson A, Löfberg R, Persson T, Salde L, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992;27(1):9–12.

Nguyen NH, Fumery M, Dulai PS, Prokop LJ, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742–753. doi: 10.1016/S2468-1253(18)30231-0

D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44:1018–1029.

Hartmann F, Stein J; Bud Mesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010 Aug;32(3):368–76.

Gross V, Bar-Meir S, Lavy A, Mickisch O, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006 Jan 15;23(2):303–12.

Matzen P. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol. 1991 Dec;26(12):1225–30.

Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016 Feb;61(2):358–70.

Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Oct 26;(10):CD007698.

Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014 May;39(10):1095– 103.

Gisbert JP, Linares PM, McNicholl AG, Mate J, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–37.

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005;353:2462–2476.

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology. 2012;142:257–65 e1-3.

Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85– 95; quiz e14-5.

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369:699–710.

Sandborn W SB, D’Haens GR, et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology. 2016:S157.

Danese S, Vermeire S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113–2128. doi: 10.1016/S0140-6736(22)00581-5

Sandborn WJ, Feagan BG, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 Sep 30;385(14):1280–1291. doi: 10.1056/NEJMoa2033617

Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392– 400.e3.

Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis. 2011;5:13. doi: 10.1002/14651858.CD000478.pub4

Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Antitumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul;21(7):1709–18.

100

Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug;22(8):1999–2015.

101

Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.

102

Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201–11.

103

Danese S, D’Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018;24(10):2106–2112. doi: 10.1093/ibd/izy076

104

Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1201–1214. doi: 10.1056/NEJMoa1900750

105

Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162–175. doi: 10.1111/apt.14422

106

Shmidt E, Kochhar G, Hartke J, et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory. Inflamm Bowel Dis. 2018;24(11):2461–2467. doi: 10.1093/ibd/izy171

107

Sands BE, Armuzzi A, Marshall JK, et al. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. J Crohns Colitis. 2018;12:49. doi: 10.1093/ecco-jcc/jjx180.063

108

Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.

109

Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–22.

110

Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227–32.

111

Parlak E, Dağli U, Ulker A, et al. Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol. 200;33(1):85–6.

112

Khan KJ, Ullman TA, Ford AC, Abreu MT, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.

113

Ohkusa T, Kato K, Terao S, Chiba T, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a doubleblind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820–9.

114

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363–8.

115

Chebli LA, LDdM Chaves, Pimentel FF, Guerra DM, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613–9.

116

Ardizzone S, Maconi G, Russo A, Imbesi V, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.

117

Халиф И.Л., Нанаева Б.А., Головенко А.О., Головенко О.В. Отдаленные результаты консервативного лечения больных с тяжелым обострением язвенного колита. Терапевтический архив. 2015;87(2):34–38. doi: 10.17116/terarkh201587234-38

Khalif I.L., Nanaeva B.A., Golovenko A.O., Golovenko O.V. Long-term results of conservative treatment of patients with severe exacerbation of ulcerative colitis. Therapeutic Archive. 2015;87(2):34–38. (in Russ.). doi: 10.17116/terarkh201587234-38

118

Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.

119

Lees CW, Heys D, Ho GT, Noble CL, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–9

120

Van Assche G, D’Haens G, NomanM, Vermeire S, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.

121

Sjoberg M, Walch A, Meshkat M, Gustavsson A, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18(2):212–8.

122

Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;5(23):65–73.

Golovenko A.O., Khalif I.L., Golovenko O.V., Veselov V.V. Predictors of infliximab efficacy in patients with severe ulcerative colitis attack. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;5(23):65–73 (in Russ.).

123

Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut. 1975;16:579–84.

124

Travis SP, Farrant JM, Ricketts C, Nolan DJ, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.

125

Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98:2363–2371.

126

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.

127

Jess T, Loftus Jr EV, Velayos FS, Harmsen WS, et al. Risk of intestinal cancer in inflammatory bowel disease: a populationbased study from olmsted county, Minnesota. Gastroenterology. 2006;130:1039–46.

128

Bergeron V, Vienne A, Sokol H, Seksik P, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol. 2010;105(11):2405–11.

129

Rutter M, Saunders B, Wilkinson K, Rumbles S, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.

130

Feuerstein JD, Rakowsky S, Sattler L, et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and highdefinition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019;90:186–195.

131

Iannone A, Ruospo M, Wong G, et al. Chromoendoscopy for surveillance in ulcerative colitis and Crohn’s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol. 2017;15:1684–1697.

132

Bessissow T, Dulai PS, Restellini S, et al. Comparison of endoscopic dysplasia detection techniques in patients with ulcerative colitis: a systematic review and network meta-analysis. Inflamm Bowel Dis. 2018;24:2518–2526.

133

Alkandari A, Thayalasekaran S, Bhandari M, et al. Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study. J Crohns Colitis. 2019;28:13(11):1394–1400.

134

Kinoshita S, Uraoka T, Nishizawa T et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. Gastrointest Endosc. 2018;87(4):1079–1084.

135

Andersen K, Vogt C, Blondin D, et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur J Radiol. 2006;58:140–6.

136

Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001;3:223–6.

137

McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis P, et al. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis. 2009;15:1256–63.

138

Marcello PW, Roberts PL, Schoetz Jr DJ, Coller JA, et al. Long-term results of the ileoanal pouch procedure. Arch Surg. 1993;128:500–3 [discussion 503–4].

139

Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis. 1997;15:172–88.

140

Meagher AP, Farouk R, Dozois RR, Kelly KA, et al. J ileal pouchanal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.

141

Fleming FJ, Francone TD, Kim MJ, Gunzler D, et al. A laparoscopic approach does reduce short-term complications in patients undergoing ileal pouch-anal anastomosis. Dis Colon Rectum. 2011;54:176–82.

142

Colombo F, Pellino G, Selvaggi F, et al. Minimally invasive surgery and stoma-related complications after restorative proctocolectomy for ulcerative colitis. A two-centre comparison with open approach. Am J Surg. 2019;217:682–8.

143

Ahmed A, Keus F, Heikens J, et al. Open versus laparoscopic [assisted] ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009;1:CD006267.

144

Tilney HS, Lovegrove RE, Heriot AG, et al. Comparison of shortterm outcomes of laparoscopic vs open approaches to ileal pouch surgery. Int J Colorectal Dis. 2007;22:531–42.

145

Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg. 2012;99:270–5.

146

Sofo L, Caprino P, Sacchetti F, Bossola M. Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a narrative review. World J Gastrointest Surg. 2016;8:556–63.

147

Setti-Carraro P, Ritchie JK, Wilkinson KH, et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut. 1994;35:1070–1075.

148

Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–127.

149

Belliveau P, Trudel J, Vasilevsky CA, et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999;42:345–352.

150

Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, et al. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis. 2011;13:177–83.

151

Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg. 2000;70:906–7.

152

Chapman JR, Larson DW, Wolff BG, Dozois EJ, et al. Ileal pouchanal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005;140:534–40.

153

Delaney CP, Dadvand B, Remzi FH, et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum. 2002;45:890–4.

154

Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg. 1999;86:493–5.

155

Ording OK, Juul S, Berndtsson I, Oresland T, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002;122:15–9.

156

Gorgun E, Remzi FH, Goldberg JM, Thornton J, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004;136:795–803.

157

Johnson P, Richard C, Ravid A, Spencer L, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004;47:1119–26.

158

Oresland T, Palmblad S, Ellstrom M, Berndtsson I, et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis. 1994;9:77–81.

159

Alves A, Panis Y, Bouhnik Y, Maylin V, et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379–85

160

Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45–51.

161

Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48:70–3.

162

Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009;52:187–92.

163

Marceau C, Alves A, Ouaissi M, Bouhnik Y, et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery. 2007;141:640.

164

Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321–9.

165

Burns EM, Bottle A, Aylin P, Clark SK, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408–17.

166

Tekkis PP, Fazio VW, Lavery IC, Remzi FH, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005;241:262–8.

167

Lepisto A, Järvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg. 2005;94:40–2. doi: 10.1177/145749690509400110

168

Edwards CM, George B, Warren B.F. Diversion colitis: new light through old windows. Histopathology. 1999. 35(1):86–7.

169

Shepherd NA, Jass JR, Duval I, Moskowitz RL, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601–7.

170

SettiCarraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis. 1998;13:103–7.

171

Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062–70.

172

Lake JP, Firoozmand E, Kang JC, Vassiliu P, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004;8:547–51.

173

Mahadevan U, Loftus Jr EV, Tremaine WJ, Pemberton JH, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8:311–6.

174

Pugliese D, Armuzzi A, Rizzo G, et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010;59(Suppl III):A13.

175

Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006;93:793–9.

176

Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012 Nov;36(10):922–8. Epub 2012 Sep 24. doi: 10.1111/apt.12060

177

Meagher AP, Farouk R, Dozois RR, Kelly KA, et al. J ileal pouchanal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.

178

Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851–6.

179

Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012–8.

180

Penna C, Tiret E, Kartheuser A, Hannoun L, et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg. 1993;80:765–7.

181

Tjandra JJ, Fazio VW, Church JM, Oakley JR, et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993;165:322–5.

182

Shen B, Lashner BA. Diagnosis and Treatment of Pouchitis. Gastroenterology & Hepatology. 2008;4(5):355–361.

183

Viazis N, Giakoumis M, Koukouratos T, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis, Journal of Crohn’s and Colitis. 2013 Nov;7(10):e457–e460.

184

Travis S, Silverberg MS, Danese S, et al. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. Journal Crohns Colitis. 2022;16(Supplement_1):i004–5

185

Peter J, Zeitz J, Stallmach A. Ustekinumab Rescue Therapy in a Patient With Chronic Refractory Pouchitis. Journal of Crohn’s and Colitis. 2018;12(8):1008–1009.

186

Сухина М.А., Образцов И.В., Михалевская В.И., Ачкасов С.И., и соавт. Алгоритм лабораторной диагностики Clostridium difficileассоциированной диареи. Журнал микробиологии, эпидемиологии и иммунобиологии (ЖМЭИ). 2018;(2):45–53.

Sukhina M.A., Obraztsov I.V., Mikhalevskaya V.I., Achkasov S.I., et al. An algorithm for laboratory diagnosis of Clostridium difficile-associated diarrhea. Journal of Microbiology, Epidemiology and Immunobiology. 2018;(2):45–53. (in Russ.).

187

Шелыгин Ю.А., Алёшкин В.А., Сухина М.А., Миронов А.Ю., и соавт. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи, и общероссийской общественной некоммерческой организации «Ассоциация колопроктологов России» по диагностике, лечению и профилактике Clostridium difficileассоциированной диареи (cdi). Колопроктология. 2018;3:7– 23. doi: 10.33878/2073-7556-2018-0-3-7-23

Shelygin Yu.A., Aleshkin V.A., Sukhina M.A., Mironov A.Yu., et al. Clinical recommendations of the national association of specialists for the healthcare related infections control and the Russian Association of coloproctology on diagnosis, treatment and prophylaxis of Clostridium difficile associated diarrhea (cdi). Koloproktologia. 2018;(3):7–23. (In Russ.). doi: 10.33878/2073-7556-2018-0-3-7-23

188

Aguado JM, Anttila VJ, Galperine T, Goldenberg SD, et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015;2(50):117–125.

189

Metan G, Türe Z, Kaynar L. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy. 2015;6(27):354–357.

190

Chiu CY, Sarwal A, Feinstein A, Hennessey K. Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019 Oct 1;8(4). pii: E173. doi: 10.3390/antibiotics8040173

191

Tschudin-Sutter S, Braissant O, Erb S, et al. Growth Patterns of Clostridium difficile — Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One. 2016;9(11):e0161711.

192

Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;5:77–83.

Fomenko O.Yu., Achkasov S.I., Titov A.Yu., Aleshin D.V., et al. Modern possibilities of improving the functional state of the locking device in patients with the presence of preventive intestinal stomas. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;5:77–83. (in Russ.).

193

Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015;5–6:16–20.

Fomenko O.Yu., Achkasov S.I., Titov A.Yu., Dzhanaev Yu.A., et al. The role of anorectal manometry, BOS therapy and tibial neuromodulation in the diagnosis and conservative treatment of anal incontinence in the elderly. Clinical gerontology. 2015;5–6:16–20 (in Russ.).

194

Rahier JF, Magro F, Abreu C, Armuzzi A, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443–68. Epub 2014 Mar 6. doi: 10.1016/j.crohns.2013.12.013

195

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005. 172(9):1169–227.

196

Franchimont D, Ferrante M, Louis E et al. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastroenterol Belq. 2018;81:49–53.

197

Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748

198

Colombel JF, Ordás I, Ullman T, Rutgeerts P, et al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb;150(2):389–95.e3. doi: 10.1053/j.gastro.2015.10.016

199

Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018.

200

Puolanne AM, Kolho KL, Alfthan H, Färkkilä M. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. Scand J Gastroenterol. 2019 Jul;54(7):849–854. doi: 10.1080/00365521.2019.1618910

201

Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019 Jun;15(6):667–677. doi: 10.1080/1744666X.2019.1593140

202

Князев О.В., Каграманова А.В., Корнеева И.А. и соавт. Значение фекального кальпротектина в мониторинге активности воспалительных заболеваний кишечника. Терапевтический архив. 2019;91(4):53–61. doi: 10.26442/00403660.2019.04.000229

Knyazev O.V., Kagramanova A.V., Korneeva I.A., et al. The importance of fecal calprotectin in monitoring the activity of inflammatory bowel diseases. Therapeutic Archive. 2019;91(4):53–61 (in Russ.). doi: 10.26442/00403660.2019.04.000229

203

Trigo-Vicente С, Gimeno-Ballester V, et al. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm. 2018 Dec;40(6):1411–1419. doi: 10.1007/s11096-018-0743-4

204

Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–848.

205

Olivera P, Zuily S. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857– 873. doi: 10.1038/s41575-021-00492-8

206

Подольская Д.В., Шапина М.В., Баранова Т.А., Тишаева И.А., и соавт. Эффективность тофацитиниба в качестве «терапии спасения» у пациентов с язвенным колитом тяжелой степени. Колопроктология. 2021;20(3):43–50. doi: 10.33878/2073-7556-2021-20-3-43-50

Podolskaya D.V., Shapina M.V., Baranova T.A., Tishaeva I.A., et al. The effectiveness of tofacitinib as a “rescue therapy” in patients with severe ulcerative colitis. Koloproktologia. 2021;20(3):43–50. (in Russ.). doi: 10.33878/2073-7556-2021-20-3-43-50

207

Kotwani P, Terdiman J, Lewin S. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. J Crohns Colitis. 2020 Jul 30;14(7):1026–1028. doi: 10.1093/ecco-jcc/jjaa018

208

Xiao Y, Benoit N, Sedano R, et al. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Dig Dis Sci. 2022. PMID: 35244825. doi: 10.1007/s10620-022-07439-2

209

Goetgebuer L, et al. Kreijne Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. Journal of Crohn’s and Colitis. 2021, 1464–1473. doi: 10.1093/ecco-jcc/jjab036

210

Sands B, Peyrin-Biroulet L, Loftus E, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1215–1226. doi: 10.1056/NEJMoa1905725

211

Bressler B, Yarur A, Silverberg M, et al. Vedolizumab and AntiTumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 7;15(10):1694–1706. doi: 10.1093/eccojcc/jjab058

212

Bressler B, Yarur A, Kopylov U, et al. Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy PostVedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn’s Disease. United European Gastroenterol J. 2019;7(8(Suppl)). Poster P1091).

213

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMA/CHMP/BWP/247713/2012. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Last accessed: September 2022.

214

IQVIA. The impact of biosimilar competition in Europe. 2021. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-ineurope-2021.pdf. Last accessed: 17 October 2022.

215

Humphry N. The Rise of Anti-TNF Biosimilars: Guidelines, RealWorld Evidence, and Challenges to Acceptance. EMJ Gastroenterol. 2022;11[Suppl 7]:2–10. doi: 10.33590/emjgastroenterol/10106137

216

Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11:26–34. doi: 10.1093/ecco-jcc/jjw198

217

Cohen H, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463–78. doi: 10.1007/s40265-018-0881-y

218

Massimi D, Barberio B, Bertani L. et al. Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study. Ther Adv Gastroenterol. 2021;14:1–11.

219

Trystram N, Abitbol V, Tannoury J. et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53:887–99.

220

Mahmmod S, Schultheiss JPD, van Bodegraven AA, et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1954–62.

221

Kaniewska M, Rosolowski M, Moniuzsko A, et al. Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients. Prz Gastroenterol. 2021;16:207–12.

222

Morris GA, McNikol M, Boyle B, et al. Increasing biosimilar utilization at a pediatric inflammatory bowel disease center and associated cost savings: show me the money. Inflamm Bowel Dis. 2022;28:531–8.

223

Barberio B, Cingolani L, Canova C, et al. A propensity scoreweighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Ther Adv Gastroenterol. 2021;14:175–82.

224

Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881–96.

225

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3–25. Epub 2016 Sep 22. doi: 10.1093/ecco-jcc/jjw168

226

Cordón JP, Arranz EM, Ramírez L, Arranz M. What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF? A. Cerpa Arencibia, C. Suarez Ferrer. Journal of Crohn's and Colitis. 2020 Jan;14 (Supplement_1):S554–S554.

227

Stavem K. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. J Mark Access Health Policy. 2021;9(1):1964792. Published online 2021 Aug 20. doi: 10.1080/20016689.2021.1964792 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381978/

228

Князев О.В., Звяглова М.Ю., Каграманова А.В., и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021;93(2):150–157. doi: 10.26442/00403660.2021.02.200624

Knyazev O.V., Zvyaglova M.Yu., Kagramanova A.V., et al. Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars. Terapevticheskii Arkhiv. 2021;93(2):150–157. (in Russ.). doi: 10.26442/00403660.2021.02.200624

The authors declare that there are no conflicts of interest present.